Inpatient colonoscopies are a common occurrence in a hospital setting with nearly 4 million annual procedures worldwide, and are typically preformed to diagnose lower GI bleeds, severe anemia and unknown abdominal pain.1 However, in an emergent situation, the preprocedural bowel preparation can represent significant challenges where up to 55% of patients can present with an insufficiently prepped colon, leading to longer procedure times, the need for repeat procedures, extended hospital stays and delayed diagnoses, all of which significantly increase costs for hospitals and interfere with quality care for patients.2
1: Keswani R., Dig Dis Sci, 2015; 60:3482–3490
We believe the Pure-Vu® System has the ability to overcome these clinical challenges by reliably and predictably moving patients through the hospital system to a successful examination. Since most of inpatient colonoscopies are currently covered under the bundled payment of a Diagnosis-Related Group (DRG) reimbursement, we believe the Pure-Vu® System has the potential to offer a new standard of care which may enhance hospital efficiency by improving quality of care, reducing the length of stay and direct costs, as well as accelerating bed turn-over for new patients.
Pure-Vu® has the potential to:
The Pure-Vu® System is currently being introduced on a pilot basis in the U.S. market, and the Company is planning to initiate a full commercial launch focused on the inpatient colonoscopy market in the U.S. and select international markets in 2019.
1: HRA Healthcare Research & Analytics - Market Research, May 2015
2: Keswani R., Dig Dis Sci, 2015; 60:3482–3490